VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
VALO-2 is a multicenter, open-label extension (OLE) study enrolling patients with genotyped
keratin mutations KRT6A, KRT6B and KRT16 who were previously treated with investigational
PTX-022 during the VALO study. The purpose of the OLE study is to investigate long term
exposure to investigational PTX-022 and evaluate safety and efficacy data. A sub-study is
included to evaluate safety and efficacy of patients with genotyped keratin mutations of
KRT6C and KRT17 not previously treated with investigational PTX-022.